IBS-C Drug Market Analysis | 2021-2026
IBS-C Drug Market Growth, Trends, Dynamics & Market Insights: 2021-2026
The IBS-C Drug Market is expected to witness an impressive growth of 9.2% CAGR in the foreseeable future.
Owing to highly prevailing modern dietary habits, such as consumption of insoluble fiber, fried foods, and excessive intake of alcohol and caffeine, there is a surge in the number of people suffering from IBS, which propels the product demand. Moreover, severe gastrointestinal infection, rising lifestyle-oriented diseases, a growing number of patients suffering from depression, and medical advancements further augment the market growth. However, stringent FDA regulations and ignorance among people as well as some serious after-effects of the drugs used to treat IBS are likely to hamper the industry growth.
What is IBS-C?
Irritable bowel syndrome (IBS) is highly prevalent in the general population and has affected significantly in terms of substantial and socio-economic impact. There are around 10-20% of the population experiencing symptoms of IBS, but 15% of affected individuals seek medical treatment.
The COVID-19 outbreak negatively affected the growth of the IBS-C Drug market. The pandemic caused added challenges for patients who are having some form of gastrointestinal infection. Due to social distancing, many hospitals have restricted appointments, and they were instead offering patient video conferencing to overcome the limitations of the market growth.
Key players operating in the IBS-C drug market are-
Based on product, the market has been classified into linaclotide, lubiprostone, stimulant laxatives, and others. The linaclotide segment accounted for a substantial market share in 2020. Linaclotide is an oral medication for the treatment of constipation. It is the first in a new class of drugs known as guanylate cyclase-C agonists. It is widely administered for relieving symptoms of irritable bowel syndrome (IBS) with constipation and for treating chronic constipation of unknown causes.
The market in North America accounted for the largest share in 2020 and is projected to continue its dominance during the review period. This is mainly attributed to the surge in prevalence of gastrointestinal infection cases, the large presence of advanced healthcare infrastructure, rise in a number of approval for novel IBS-C Drug, as well as presence of major market participants. In addition, the surge in R&D activities in the healthcare sector and enhancement of healthcare infrastructure, and presence of major players operating in the region, which further proliferates the regional growth.
To get the full scope of the report, Register Here
Here is the list of the group of customers that the market hopes to have the greatest opportunity to convert-
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.
What deliverables will you get in this report?
Key questions this report answers
Relevant contents in the report
How big is the sales opportunity?
In-depth analysis of the IBS-C Drug Market
How lucrative is the future?
Market forecast and trend data and emerging trends
Which regions offer the best sales opportunities?
Global, regional and country level historical data and forecasts
Which are the most attractive market segments?
Market segment analysis and forecast
Which are the top players and their market positioning?
Competitive landscape analysis, Market share analysis
How complex is the business environment?
Porter’s five forces analysis, PEST analysis, Life cycle analysis
What are the factors affecting the market?
Drivers & challenges
Will I get the information on my specific requirement?
10% free customization
This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.
With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:
Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to firstname.lastname@example.org.
The IBS-C drug market is expected to witness an impressive growth of 9.2% CAGR in the foreseeable future.
Catalent Pharmaceuticals Solutions (US), Nestle (Switzerland), Abbott Laboratories (US), Synergy Pharmaceuticals (US), Sucampo Pharmaceuticals (US), Novartis Pharma Ag (Switzerland), Astellas Pharmaceuticals (Japan), Ardelyx, Inc (US), Synthetic Biologics, Inc (US), and Teva Pharmaceutical Industries (Israel) are the key players in the IBS-C drug market.
Severe gastrointestinal infection, rising lifestyle-oriented diseases, a growing number of patients suffering from depression, and medical advancements are the factors driving the growth of IBS-C drug market.
North America accounted for the largest share in the IBS-C drug market in 2020.
The linaclotide segment accounted for a substantial share in the IBS-C drug market in 2020.
IBS-C Drug distributors, IBS-C Drug suppliers, IBS-C Drug manufacturers, Hospitals, Government bodies are the target audience in the IBS-drug market.